PDCD1 and neoplasm: A photodynamic immunostimulator (PCS) designed to simultaneously down-regulate and block programmed cell death 1 (PD-L1) ligand in tumor cells enables effective inhibition of breast cancer growth by photodynamic therapy (PDT) and activation of the systemic immune response.